Conjugated TLR7 and/or TLR8 and TLR2 agonists

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9567336
APP PUB NO 20140141033A1
SERIAL NO

13832179

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INVIVOGEN31400 TOULOUSE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Debin, Arnaud Escalquens, FR 4 27
Drocourt, Daniel Saint Orens de Gameville, FR 15 172
Lioux, Thierry Balma, FR 11 102
Perouzel, Eric Toulouse, FR 13 124
Tiraby, Gerard Toulouse, FR 15 195
Vernejoul, Fabienne Toulouse, FR 13 102

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 14, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00